Late breaking abstracts

Monday 27 May 15:45-17:15

Late Breaking session on pharmacology of dyslipidemia

Chair:
  • Francois Mach, Switzerland
  • Alexandros Tselepis, Greece

LDL-C LOWERING AMONG PATIENTS WITH LDL-C ABOVE 4.9 MMOL/L AND FEATURES SUGGESTING A GENETIC VULNERABILITY TO CARDIOVASCULAR DISEASE: ANALYSES FROM THE 4S TRIAL

Antonio J Vallejo-Vaz, London, United Kingdom

METABOLOMIC CONSEQUENCES OF PCSK9 INHIBITION COMPARED WITH STATIN THERAPY

Peter Würz, Helsinki, Finland

INCLISIRAN DURABLY LOWERS LDL-C AND PCSK9 EXPRESSION IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: THE ORION-2 PILOT STUDY

Frederick Raal, Johannesburg, South Africa

SAFETY, TOLERABILITY AND LDL-C REDUCTION WITH A NOVEL ANTI-PCSK9 RECOMBINANT FUSION PROTEIN (LIB003): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY

Evan Stein, Chicago, USA

EFFICACY AND SAFETY OF BEMPEDOIC ACID + EZETIMIBE FIXED-DOSE COMBINATION IN PATIENTS AT HIGH CVD RISK AND WITH ELEVATED LDL-C RECEIVING MAXIMALLY TOLERATED STATIN THERAPY

Christy Ballantyne, Houston, USA


Tuesday 28 May 15:30-17:00

Late Breaking session on experimental atherosclerosis and genetics

Chair:
  • Geesje M. Dallinga-Thie, The Netherlands
  • Bart Staels, France

FUNCTION AND MUTATION OF NETRIN-1 IN PREMATURE ATHEROSCLEROSIS

Caroline Bruikman, Amsterdam, The Netherlands

A HUMAN-LIKE COMPOSITION OF THE CIRCULATING BILE ACID POOL IMPACTS ON PLASMA LDL CHOLESTEROL IN MICE

Jan Freark De Boer, Groningen, The Netherlands

A COMMON VARIANT IN THE NLRP3 INFLAMMASOME LOCUS ASSOCIATES WITH MORTALITY

Winfried März, Mannheim, Germany

GENETICS OF HUMAN PLASMA LIPIDOME AND ITS LINK TO DISEASES SUSCEPTIBILITY

Rubina Tabassum, Helsinki, Finland

PREMATURE MORBIDITY AND MORTALITY AMONG DIAGNOSED AND POTENTIALLY UNDIAGNOSED FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN THE GENERAL POPULATION: AN OBSERVATIONAL STUDY OF OVER 1.7 MILLION HEALTH RECORDS

Kausik Ray, London, UK